Abstract:Objective To evaluate the therapeutic efficacy and safety of TACE combined with hepatic arterial infusion chemotherapy(HAIC) using oxaliplatin(OXA),5-fluorouracil(5Fu) and folinic acid(FA) for patients with intermediate and advanced hepatocellular carcinoma(HCC).Methods A total of 50 patients of pathologically or clinically proved inoperable HCC with no distant metastases,encountered during the period from July 2008 to December 2010 in authors' hospital,were enrolled in this study.All patients underwent TACE combined with HAIC by using OXA/5-Fu/CF.After TACE,HAIC with OXA(60-75mg/m2 in 0-4 hours),CF(200 mg /m2 in 4-6 hours) and 5-Fu(1 000-1 500 mg/m2 in 6-24 hours) via the indwelling catheter was carried out,and the therapeutic course was repeated every 4-6 weeks,until complete response(mRECIST version 1.1) was obtained,or liver function turned to Child-Pugh C,or distant metastases developed,or the adverse effects became intolerable to the patient.After the treatment,the patients were kept under close observation for untoward reactions.The laboratory examinations,enhanced CT or MRI were periodically performed to evaluate the therapeutic results.All the patients were followed up regularly.Results A total of 232 therapeutic courses of TACE combined with HAIC using OXA/5-Fu/CF were completed in 50 patients.Complete response,partial response,stable disease and progressive disease were obtained in 10,21,6 and 13 patients,respectively.Objective response rate was 74%,and disease control rate was 62%.The median follow-up time was 17.1 months(ranged 2.6-37.1 months),while the median PFS and median OS for all the patients were 9.3 and 21.4 months,respectively.The 1-year and the 2 year survival rates were 76% and 44%,respectively.The patients who had a liver function of Child-Pugh A(P = 0.006) and a total bilirubin 34.2 umol/L(P = 0.023) and with no tumor vessel invasion(P = 0.003) carried a better prognosis than the patients of control group(Kaplan-Meier method,Logrank test,P 0.05).Multivariate analysis revealed that the presence of tumor vessel invasion(P = 0.045) was a harmful independent prognostic factor.Adverse reactions(Ⅲ-Ⅳ grade) were less common,and neurotoxicity(Ⅲ grade) was observed in only 2 patients.No indwelling catheter-related complications occurred.Conclusion For inoperable intermediate and advanced HCC with no distant metastases,TACE combined with HAIC using OXA/5Fu/FA is a safe treatment with reliable effectiveness.

TACE Combined with Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin, 5-Fluorouracil and Folinic Acid for Intermediate and Advanced Hepatocellular Carcinomas

Three-dimensional Conformal Radiotherapy in Combination with Transcatheter Arterial Chemoembolization in the Treatment of Hepatocellular Carcinoma.

[A retrospective controlled study of TACE-HAIC-targeted-immune quadruple therapy for intermediate and advanced-stage hepatocellular carcinoma]

3:45 PM Abstract No. 303 Hepatic Arterial Infusion Chemotherapy (HAIC) Using Oxaliplatin Plus 5-Fluorouracil Versus Transarterial Chemoembolization/embolization for Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis

The Safety and Efficacy of Hepatic Arterial Infusion Chemotherapy Combined with PD-(L)1 Inhibitors and Molecular Targeted Therapies for the Treatment of Intermediate and Advanced Hepatocellular Carcinoma Unsuitable for Transarterial Chemoembolization

Safety and efficacy of hepatic arterial infusion chemotherapy with raltitrexed and oxaliplatin post-transarterial chemoembolization for unresectable hepatocellular carcinoma

Hepatic Arterial Infusion Chemotherapy with Modified FOLFOX as an Alternative Treatment Option in Advanced Hepatocellular Carcinoma Patients with Failed or Unsuitability for Transarterial Chemoembolization

Analysis of the safety and effectiveness of TACE combined with targeted immunotherapy in the treatment of intermediate and advanced hepatocellular carcinoma

The safety and efficacy of TACE combined with HAIC, PD-1 inhibitors, and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a retrospective study

Hepatic Arterial Infusion Chemotherapy Combined with Tyrosine Kinase Inhibitors and PD-1 Inhibitors in Hepatocellular Carcinoma

Transcatheter Arterial Chemoembolization Combined with Hepatic Arterial Infusion Chemotherapy Versus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-analysis

Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibodies with Hepatic Arterial Infusion Chemotherapy or Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma

Both anti-angiogenesis and immunotherapy combined with interventional therapy in treatment of hepatocellular carcinoma: effect of hepatic artery infusion chemotherapy compared with hepatic artery chemoembolization

Hepatic Arterial Infusion Chemotherapy with Oxaliplatin Plus Raltitrexed as an Alternative Option in Advanced Hepatocellular Carcinoma Patients with Failure of, or Unsuitability for, Transarterial Chemoembolization

Atezolizumab and bevacizumab plus transarterial chemoembolization and hepatic arterial infusion chemotherapy for patients with high tumor burden unresectable hepatocellular carcinoma: A multi-center cohort study

Efficacy and safety of HepaSphere drug-eluting bead transarterial chemoembolization combined with hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma.

Efficacy and safety of hepatic arterial infusion chemotherapy combined with transarterial embolization for unresectable hepatocellular carcinoma: A propensity score‐matching cohort study

Clinical efficacy of HAIC (FOLFOX) combined with lenvatinib plus PD-1 inhibitors vs. TACE combined with lenvatinib plus PD-1 inhibitors in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombus and arterioportal fistulas

Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy Combined a Tyrosine Kinase Inhibitor for Treatment of Large Hepatocellular Carcinoma

Transarterial chemoembolization with hepatic arterial infusion chemotherapy plus S-1 for hepatocellular carcinoma